Enzyme News and Research

RSS

Protein inhibitor drug found to be safe and effective in treating patients with acute myeloid leukemia

Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia with relapsed or refractory disease.

4 Jun 2018

Highly stable DNA origami nanostructures may pave way for a plethora of biomedical applications

The DNA origami technique is a widely used method for making complex, yet well-defined nanostructures, with applications in biophysics, molecular biology, as well as drug and enzyme delivery.

31 May 2018

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

In most of the Western World, cancer is the primary cause of death in children over the age of one. Existing treatments for adult cancer patients are not particularly effective for children.

31 May 2018

Scientists find enzyme that breaks down plasmalogens in Alzheimer's disease patients

Alzheimer's disease patients lose up to 60% of a component called plasmalogen from the membranes of the cells in their brains, but it's still not known how or why.

31 May 2018

Researchers trigger natural defense mechanism to alleviate intestinal inflammation

Treating inflammatory diseases of the bowel is extremely challenging: Genes, gut microbes and disrupted immune function all contribute.

31 May 2018

New RNA deletion tool could help create drugs that correct genetic diseases

As scientists gain insights into which genes drive diseases, they are pursuing the next logical question: Can gene editing technologies be developed to treat or even cure those diseases? Much of that effort has focused on developing technologies such as CRISPR-Cas9, a protein-based system.

30 May 2018

Anti-inflammatory strategy could lead to improved survival of children with neuroblastoma

Researchers at Karolinska Institutet and Karolinska University Hospital have discovered that an anti-inflammatory drug candidate inhibiting the prostaglandin E2 producing enzyme mPGES-1 in the tumor stroma reduces tumor growth in experimental neuroblastoma models.

28 May 2018

Fewer women meet eligibility criteria for clinical trial of heart failure drugs, study finds

Clinical trial enrolment favors men, according to a study presented today at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology congress. The study found that fewer women meet eligibility criteria for trials of heart failure medication.

28 May 2018

FDA approves novel enzyme therapy for adults with rare and serious genetic disease

The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU).

25 May 2018

International researchers succeed in stopping growth of mesothelioma in model animals

An international team led by researchers from the Technion-Israel Institute of Technology and NYU Langone Health have succeeded in stopping the growth of mesothelioma in model animals by inhibiting the heparanase enzyme.

24 May 2018

Scientists uncover the cause of insulin resistance in obesity

A team of international researchers has identified a pathway by which obesity results in reduced insulin sensitivity.

24 May 2018

Scientists report new strategy for fighting bacteria

Antimicrobial resistance is a major medical problem worldwide, impacting both human health and economic well-being.

24 May 2018

Study shows bacteria behave differently in humans compared to the lab

A recent study has shown that deadly bacteria such as Pseudomonas aeruginosa behave differently in the humans, compared to a laboratory setting.

23 May 2018

ToolGen's CRISPR/Cas9 gene editing platform improves T-cell anti-tumor activity in mouse model

ToolGen, Inc., a biotechnology company specializing in genome editing, today announced data demonstrating that blocking a molecular pathway that down-regulates T-cell activity with the Company’s CRISPR/Cas9 gene editing platform results in increased T-cell receptor signaling, in vitro, and in improved anti-tumor activity when tested against in a mouse glioblastoma tumor model.

22 May 2018

CRISPR-Cas9-based strategy allows researchers to precisely alter hundreds of different genes

Geneticists have been using model organisms ranging from the house mouse to the single-cell bakers' yeast, Saccharomyces cerevisiae, to study basic biological processes that regulate human development and physiology, and that can be compromised in various diseases.

22 May 2018

Researchers use MR spectroscopy to investigate mechanisms behind targeted treatment for gliomas

Using a novel imaging method, a Massachusetts General Hospital research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas.

21 May 2018

Natural antioxidant bilirubin may provide cardiovascular benefits

Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.

18 May 2018

Raising Awareness of Childhood Dementia

The Dementia Strikes Children Too campaign aims to raise awareness of childhood dementia, drive for better clinical education of this group of diseases, and put in place the systems and tools for earlier diagnosis.

18 May 2018

Ovarian cancer therapy may help treat patients with aggressive pancreatic cancer

A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

18 May 2018

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

17 May 2018

Enzyme News and Research

Protein inhibitor drug found to be safe and effective in treating patients with acute myeloid leukemia

Highly stable DNA origami nanostructures may pave way for a plethora of biomedical applications

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

Scientists find enzyme that breaks down plasmalogens in Alzheimer's disease patients

Researchers trigger natural defense mechanism to alleviate intestinal inflammation

New RNA deletion tool could help create drugs that correct genetic diseases

Anti-inflammatory strategy could lead to improved survival of children with neuroblastoma

Fewer women meet eligibility criteria for clinical trial of heart failure drugs, study finds

FDA approves novel enzyme therapy for adults with rare and serious genetic disease

International researchers succeed in stopping growth of mesothelioma in model animals

Scientists uncover the cause of insulin resistance in obesity

Scientists report new strategy for fighting bacteria

Study shows bacteria behave differently in humans compared to the lab

ToolGen's CRISPR/Cas9 gene editing platform improves T-cell anti-tumor activity in mouse model

CRISPR-Cas9-based strategy allows researchers to precisely alter hundreds of different genes

Researchers use MR spectroscopy to investigate mechanisms behind targeted treatment for gliomas

Natural antioxidant bilirubin may provide cardiovascular benefits

Raising Awareness of Childhood Dementia

Ovarian cancer therapy may help treat patients with aggressive pancreatic cancer

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Biochemical Assays for Efficient Hit Prioritization After Screening eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo